TITLE

FDA requests withdraw of sibutramine from US market

PUB. DATE
December 2010
SOURCE
Cardiology Today;Dec2010, Vol. 13 Issue 12, p24
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article reports that a recommendation against the continued prescription and use of sibutramine has been issued by the U.S. Food and Drug Administration (FDA) in line with the elevated cardiovascular (CV) risks observed in some patients taking the drug.
ACCESSION #
55545919

 

Related Articles

  • the truth about DIET PILLS. Marinos, Sarah // Good Health (Australia Edition);Apr2011, p62 

    The article explores the business of diet pills for losing weight. The Sibutramine Cardiovascular OUTcomes (SCOUT) study linked the reductil to 16 percent incidence of heart attack and stroke in obese patients. In 2011, approximately 4.2 per cent of the 789.6 million dollars weight-loss market...

  • Sibutramine.  // Reactions Weekly;5/6/2006, Issue 1100, p20 

    Presents the study "QT Interval Prolongation Associated With Sibutramine Treatment," which appeared in the April 2006 issue of the "British Journal of Clinical Pharmacology." Medical history of the patient, who developed QT interval prolongation and heart arrest during treatment with...

  • Phen-Fen all over again? Brietzke, Carol // Cosmopolitan;Aug98, Vol. 225 Issue 2, p90 

    Introduces Meridia, a prescription pill diet pill. Features of the drug; How Meridia works.

  • Sorry, sorry, sorry. Iheanacho, Ike // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;2/13/2010, Vol. 340 Issue 7742, p370 

    The author ponders on the suspension of the license for antiobesity drug sibutramine in Europe.

  • Sibutramine.  // Reactions Weekly;6/8/2013, Issue 1456, p32 

    The article presents a case study of a 40-year old woman who became acutely psychotic after taking the herbal slimming product Irem Bitkisel Zayiflama containing sibutramine.

  • Weight-loss drug fattens heart risks.  // Consumer Reports;Dec2003, Vol. 68 Issue 12, p57 

    Discusses the heart risks associated with the weight-loss drug Sibutramine manufactured by Abbott Laboratories. Mechanism of action of the drugs; Number of people taking the drugs that developed cardiovascular disease; Effect of the drug on blood pressure and heart rate.

  • EFFECTIVENESS OF SIBDTRAMINE. Lieberman, Joseph A. // Journal of Family Practice;Oct2002, Vol. 51 Issue 10, p863 

    Two letters to editor are presented concerning the article about racial factors in the use of sibutramine in the long-term management of obesity.

  • Antidote. Siegel, Marc // Medical Marketing & Media;Apr2006, Vol. 41 Issue 4, p14 

    The article examines some weight loss drugs in the United States. Xenical or Orlistat are drugs that hinder fat absorption into the gastrointestinal tract. An appetite suppressant, Meridia prevents the reabsorption of serotonin, a hormone in the brain that is released when a patient is full from...

  • Sibutramine.  // Reactions Weekly;3/25/2006, Issue 1094, p19 

    The article presents the study "Sibutramine Use Associated With Reversible Hepatotoxicity," which appeared in the November 2005 issue of "Annals of Internal Medicine." The medical history of the elderly woman with acute cholestatic hepatitis is described. The serum levels after the woman's liver...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics